[
    [
        {
            "time": "",
            "original_text": "【东吴医药】医药生物行业2019H1业绩总结：行业增速放缓，龙头引领增长，聚焦创新药产业链、创新生物制品、医疗服务等景气细分赛道",
            "features": {
                "keywords": [
                    "医药生物",
                    "行业增速",
                    "龙头引领",
                    "创新药产业链",
                    "创新生物制品",
                    "医疗服务"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【东吴医药】医药生物行业2019H1业绩总结：行业增速放缓，龙头引领增长，聚焦创新药产业链、创新生物制品、医疗服务等景气细分赛道",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "83只超级牛股最新评级 这些公司目标涨幅空间还有30%以上（名单）",
            "features": {
                "keywords": [
                    "超级牛股",
                    "目标涨幅",
                    "30%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "83只超级牛股最新评级 这些公司目标涨幅空间还有30%以上（名单）",
                "Correlation": 6,
                "Sentiment": 9,
                "Importance": 7,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 10,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "中信建投秋季轻工策略：坚守优势赛道及龙头公司",
            "features": {
                "keywords": [
                    "中信建投",
                    "秋季策略",
                    "轻工",
                    "优势赛道",
                    "龙头公司"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "轻工制造"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中信建投秋季轻工策略：坚守优势赛道及龙头公司",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "医药生物9月投资逻辑：核心资产仍为投资方向，优选业绩增长加速或估值合理标的",
            "features": {
                "keywords": [
                    "医药生物",
                    "9月投资逻辑",
                    "核心资产",
                    "业绩增长",
                    "估值合理"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物9月投资逻辑：核心资产仍为投资方向，优选业绩增长加速或估值合理标的",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]